Our investigations build on a Ca~V~1.4 channel mutation underlying congenital stationary night blindness^[@R15]^. This mutation yields a premature stop that deletes the distal carboxy tail (DCT) of these retinal Ca^2+^ channels, and produces a surprising emergence of their Ca^2+^ regulation by CaM^[@R11],[@R12]^ (Ca^2+^-dependent inactivation, CDI). Full-length Ca~V~1.4 channels lack CDI^[@R11],[@R12]^, thereby maintaining Ca^2+^-driven transmitter release at tonically depolarized retinal synapses. Hence, the emergence of CDI likely impairs vision. Mechanistically, the DCT contains an ICDI module that is reported to somehow 'switch off' the latent CDI of Ca~V~1.4 channels^[@R11],[@R12]^.

[Figure 1](#F1){ref-type="fig"} summarizes our initial characterization of ICDI effects. Because Ca~V~1.4 channels yield diminutive currents^[@R16]^, we appended the DCT of the main Ca~V~1.4 subunit (α~1F~) onto the core of better-expressing Ca~V~1.3 channels (main subunit α~1D~). This previous approach permits robust investigation of DCT effects^[@R11],[@R12]^. As baseline, [Fig. 1a](#F1){ref-type="fig"} displays the CDI of core Ca~V~1.3 channels (left, α~1DΔ~), similar to natural short splice variants^[@R8]^. Core channels contain all elements required for CDI^[@R6],[@R17]^, including the IQ domain for apoCaM preassociation^[@R6]^, and EF-hand-like region for CDI transduction^[@R18]^. Depolarization thereby evoked rapidly decaying Ca^2+^ current (middle, red trace), indicative of strong CDI. Since Ba^2+^ binds CaM poorly^[@R17]^, the slow Ba^2+^ current decay (black trace) delineates the background inactivation of a distinct voltage-dependent process^[@R6],[@R7]^ (VDI). Thus, the fraction of peak current remaining after 50-msec depolarization (right, *r*~50~) relates intimately to inactivation, with the difference between Ca^2+^ and Ba^2+^ *r*~50~ relations indexing CDI (*f*~50~). Appending the Ca~V~1.4 DCT onto the Ca~V~1.3 core ([Fig. 1b](#F1){ref-type="fig"}, left) strikingly reduced CDI (middle and right) versus control (dashes) ([Supplemental 1.2](#SD2){ref-type="supplementary-material"}). Importantly, the DCT did not altogether abolish CDI as reported before^[@R11],[@R12]^, but spared a clear residuum. This difference foreshadowed major mechanistic and biological consequences.

Hints of these consequences came by qualitative consideration of underlying mechanism. As background, we recapitulated coarse structural underpinnings of DCT effects. To confirm DCT collaboration with core channel elements^[@R11],[@R12]^, we showed the lack of DCT effects on Ca~V~2.2 channels ([Supplemental 1.3](#SD2){ref-type="supplementary-material"}), which presumably lack complementing modules. As well^[@R10],[@R12]^, only ICDI and A sub-segments ([Fig. 1b](#F1){ref-type="fig"}, left) are required ([Supplemental 1.4](#SD2){ref-type="supplementary-material"}). Beyond these initial points of clarity, actual DCT mechanisms remain controversial. One group used GST pulldowns of channel peptides to support an allosteric mechanism ([Supplemental 1.5](#SD2){ref-type="supplementary-material"}), where the ICDI associates with an EF-hand-like module to eliminate CDI transduction^[@R12]^ ([Fig. 1a](#F1){ref-type="fig"}, left), but leaves apoCaM/channel binding unchanged. By contrast, another group employed channel peptide FRET to advance a competitive mechanism ([Supplemental 1.5](#SD2){ref-type="supplementary-material"}), where ICDI competes with apoCaM for binding near the channel IQ domain ([Fig. 1a](#F1){ref-type="fig"}, left), thus inhibiting CDI by displacing CaM from channels^[@R11]^.

To aid resolution, we pursued two preliminary approaches. First, live-cell FRET 2-hybrid assays^[@R6],[@R17]^ tested whether the Ca~V~1.4 ICDI ([Fig. 2a](#F2){ref-type="fig"}, CFP fused to ICDI, ECFP--ICDI~F~) could bind the presumed apoCaM preassociation module of Ca~V~1.3 (YFP fused to PreIQ~3~--IQ--A from [Fig. 1b](#F1){ref-type="fig"}, EYFP--PreIQ~3~--IQ~D~--A~F~; [Supplemental 2.1](#SD2){ref-type="supplementary-material"}). We thus resolved a high-affinity *in situ* binding curve ([Fig. 2a](#F2){ref-type="fig"}), where FRET strength (*FR*) is plotted cell-by-cell versus free ECFP--ICDI~F~ concentration (*D*~free~, free donor). By contrast to prior analyses utilizing single-number FRET indices^[@R11]^, our binding-curve clearly excludes low-affinity interaction, and a similar binding curve held true for partners solely derived from Ca~V~1.4 ([Supplemental 2.2](#SD2){ref-type="supplementary-material"}). We also confirmed avid binding between apoCaM (ECFP--CaM~WT~ in resting cells) and this EYFP--PreIQ~3~--IQ~D~--A~F~ module^[@R6]^ ([Fig. 2b](#F2){ref-type="fig"}). More telling, the ICDI (without fluorophore) attenuated the same apoCaM interaction ([Fig. 2c](#F2){ref-type="fig"}, gray zone), suggesting that ICDI and apoCaM could vye for IQ occupancy ([Supplemental Fig. 2.2b](#SD2){ref-type="supplementary-material"}). In all, these data confirmed the potential for competition, but pertained only to peptides, without guarantee of analogous events within intact channels.

Accordingly, a second provisional approach specifically targeted the holochannel configuration. Scrutiny of mechanisms ([Supplemental 1.5](#SD2){ref-type="supplementary-material"}) revealed that manipulating apoCaM levels would affect CDI only in the competitive, but not strict allosteric framework. Indeed, elevating CaM sharply reversed ICDI effects ([Fig. 2d](#F2){ref-type="fig"}, middle), and apoCaM chelation eliminated residual CDI ([Fig. 2d](#F2){ref-type="fig"}, right; [Supplemental 2.3](#SD2){ref-type="supplementary-material"}). Importantly, augmenting CaM also boosted CDI of full-length Ca~V~1.4 channels ([Fig. 2e](#F2){ref-type="fig"}, cf., ref. [@R19]). Overall, both preliminary approaches supported competition, and the residual CDI seen earlier ([Fig. 1b](#F1){ref-type="fig"}) appeared to reflect incomplete competition. Still, these data neither excluded more nuanced allosteric mechanisms^[@R20]^, nor revealed whether biologically relevant CaM fluctuations could modulate CDI.

These limitations might be overcome, if only the free apoCaM concentration could be quantified within the very cells where CDI was measured. If so, one could delineate the holochannel equivalent of classic enzyme inhibition plots^[@R20]^, which rigorously distinguish among mechanisms. Accordingly, we incorporated a recently developed optical FRET-based sensor of apoCaM, BSCaM~IQ~. Here, CFP and YFP flank the apoCaM binding site of neuromodulin^[@R9]^ ([Fig. 3a](#F3){ref-type="fig"}), such that the overall FRET is determined by free apoCaM concentration. We confirmed the limiting behaviors by coexpressing BSCaM~IQ~ with excess CaM ([Fig. 3b](#F3){ref-type="fig"}, blue line at *FR*~min~) or CaM-chelating peptides (green line at *FR*~max~; [Supplemental 3.1](#SD2){ref-type="supplementary-material"}). As expected, *FR* was nearly independent of isolated CFP fluorescence (*S*~CFP~), an approximate measure of sensor expression in each cell. By contrast, when BSCaM~IQ~ was expressed alone, *FR* demonstrated a comforting rise towards *FR*~max~ ([Fig. 3b](#F3){ref-type="fig"}, black line), as anticipated for a sensor that itself chelates and decreases free apoCaM. With reassurance of BSCaM~IQ~ performance in our system, we coexpressed BSCaM~IQ~ and Ca^2+^ channels, and measured free apoCaM concentration before determining CDI in the same cell ([Fig. 3c](#F3){ref-type="fig"}). If free apoCaM were varied among cells by CaM overexpression or chelation, the resulting CDI versus apoCaM plot would rigorously distinguish among mechanisms. Specifically, using the relation between FRET and free apoCaM concentration in our cells^[@R9]^ ([Supplemental 3.2](#SD2){ref-type="supplementary-material"}), the exact signature of competition^[@R20]^ becomes as shown in [Fig. 3d](#F3){ref-type="fig"} (right, gray curves) and $$\mathit{CDI} = \mathit{CDI}_{\max}\  \cdot \ \frac{S_{b}}{S_{b}\  \cdot \ (1 - r) + r};r = K_{d­{channel}­{apparent}}/K_{d­{sensor}}$$where *CDI*~max~ is the maximal CDI without ICDI; *K*~d-channel-apparent~ is the apparent dissociation constant of channels for apoCaM (with competitive inhibitor); *K*~d-sensor~ is the dissociation constant of BSCaM~IQ~ for apoCaM^[@R9]^ (2.3 μM); and *S*~b~ is the fraction of sensor bound to apoCaM ([Supplemental 3.3](#SD2){ref-type="supplementary-material"}). As [Fig. 3b](#F3){ref-type="fig"} shows, *S*~b~ is directly determined from *FR*, and ranges from 0 to 1 with increasing apoCaM. If ICDI competition is strong (*r* \> 1), curves will be upwardly concave ([Fig. 3d](#F3){ref-type="fig"}, right, gray curves); if weak (*r* \< 1), curves will be downwardly concave.

[Figure 3d](#F3){ref-type="fig"} also displays the experimental outcome for core Ca~V~1.3 channels affixed to the Ca~V~1.4 DCT (α~1DΔ~--(ABI)~F~, from [Fig. 1b](#F1){ref-type="fig"}). In the *CDI*--*S*~b~ plot on the right, each symbol corresponds to a single cell, and together these data fit remarkably well to the competitive scheme (red curve, [Eq. 1](#FD1){ref-type="disp-formula"}). On the left, current traces from exemplar cells (i, ii, and iii) explicitly demonstrate the appropriate increase of CDI with growing *S*~b~ and apoCaM. Importantly, parallel analysis of core Ca~V~1.3 channels revealed far greater apoCaM affinity ([Fig. 3e](#F3){ref-type="fig"}), yielding maximal CDI throughout. Hence, the upward concavity in [Fig. 3d](#F3){ref-type="fig"} is a genuine ICDI effect, not an unanticipated property of the Ca~V~1.3 core. Critically, at high apoCaM (*S*~b~ \~ 1), CDI of both constructs converged, yielding a hallmark of competition^[@R20]^.

Buoyed by advances for the retinal Ca~V~1.4 DCT, we wondered whether *CDI*--*S*~b~ analysis might uncover like DCT mechanisms in other Ca^2+^ channel subtypes, with yet broader distribution and impact. We considered a long splice variant of the human Ca~V~1.3 channel^[@R10]^ (α~1D--long\[hum\]~), which contains a DCT homologous to that in Ca~V~1.4. This long variant has recently been reported to exhibit decreased CDI^[@R10]^ compared to a short variant akin to core channels (e.g., [Fig. 3e](#F3){ref-type="fig"}). It thus seemed plausible that a competitive ICDI mechanism could extend to these channels, an important possibility given the wide distribution of Ca~V~1.3 channels^[@R13],[@R14]^, and the predominance of the long variant throughout brain^[@R10]^. Complicating this view, however, were our prior observations that corresponding long and short variants of rat Ca~V~1.3 channels exhibit no difference in CDI^[@R8]^. Indeed, all experiments to this point used the rat Ca~V~1.3. Accordingly, we undertook *CDI*--*S*~b~ analysis of long Ca~V~1.3 variants from both human and rat. The long Ca~V~1.3 variant of human ([Fig. 3f](#F3){ref-type="fig"}) clearly adhered to a competitive ICDI mechanism, with maximal CDI equivalent to that of core channels (cf., [Fig. 3d](#F3){ref-type="fig"}). This argues that long forms of Ca~V~1.3 and Ca~V~1.4 channels do share a common ICDI mechanism. However, the *CDI*--*S*~b~ relation for the long Ca~V~1.3 variant of humans differs quantitatively from that with the Ca~V~1.4 DCT (cf., [Figs. 3f, d](#F3){ref-type="fig"}), indicating that the strength of ICDI competition is customized by channel isoform. Indeed, the long Ca~V~1.3 variant of rat exhibited extreme customization ([Fig. 3g](#F3){ref-type="fig"}). Here, *CDI*--*S*~b~ analysis unmasks competitive inhibition, but the competition is weak enough that CDI remains maximal, except with overt chelation of apoCaM (at *S*~b~ \~ 0). The steep saturation of this *CDI*--*S*~b~ relation thus explains prior data that CDI was unaffected by the rat Ca~V~1.3 DCT, as no depletion was used^[@R8]^. Importantly, the *CDI*--*S*~b~ curve for the long rat variant ([Fig. 3g](#F3){ref-type="fig"}) is distinct from that for the Ca~V~1.3 core ([Fig. 3e](#F3){ref-type="fig"}), where CDI stayed maximal throughout. Hence, the rat Ca~V~1.3 DCT entails customization, not elimination of the competitive inhibitory mechanism ([Supplemental 3.4](#SD2){ref-type="supplementary-material"}).

The similarity of DCT elements, particularly of human and rat Ca~V~1.3, suggested that minute differences produce extremes of tuning. Indeed, we found that a single valine-to-alanine switch within the ICDI explains the difference (human:rat, ICDI position 47; [Supplemental 3.5](#SD2){ref-type="supplementary-material"}).

While the *CDI*--*S*~b~ analysis established a competitive inhibitory mechanism at the holochannel level, still critically unresolved was whether the ICDI/IQ peptide interactions studied thus far ([Fig. 2c](#F2){ref-type="fig"}) were relevant to holochannel competition, especially given the multiplicity of CaM sites in channels^[@R6],[@R17],[@R21],[@R22]^. This is a generic challenge for large signaling complexes. Importantly, enzyme analysis could be extended to resolve even this ambiguity. [Fig. 4a](#F4){ref-type="fig"} summarizes our data for competitive inhibition in holochannels, recasting *CDI*--*S*~b~ data into classic reciprocal-plot form^[@R20]^, where channel CDI (*f*~50~) corresponds to enzyme catalytic velocity *V*, and apoCaM to enzyme substrate *S*. Visual accord with the textbook signature of competition underscores the insights already provided by *in situ* holochannel biochemistry. Beyond this, if ICDI/IQ binding actually underlies holochannel competition, enzyme analysis additionally predicts a linear relation between the apparent apoCaM dissociation constant for holochannels (*K*~d-channel-apparent~, [Eq. 1](#FD1){ref-type="disp-formula"}) and the reciprocal of the peptide dissociation constant (1 / *K*~d-FRET-peptide~) $$K_{d­{channel}­{apparent}} = K_{d­{channel}}\  \cdot \ \lbrack{ICDI}\rbrack\  \cdot \ (1/K_{d­{FRET}­{peptide}}) + K_{d­{channel}}$$where *K*~d-channel~ is the holochannel dissociation constant for apoCaM without inhibitor, and \[ICDI\] is the effective concentration of ICDI at the channel preassociation site for apoCaM^[@R20]^ ([Supplemental 4.1](#SD2){ref-type="supplementary-material"}) Conversely, if peptide interactions are peripheral or the inhibitory mechanism not strictly competitive, this relation will likely fail ([Supplemental 4.2](#SD2){ref-type="supplementary-material"}). To test this prediction, we noted that *CDI*--*S*~b~ analysis had already determined *K*~d-channel-apparent~ for channels with three different ICDIs ([Figs. 3d, f, g](#F3){ref-type="fig"}; [Fig. 4a](#F4){ref-type="fig"}). Also, *K*~d-FRET-peptide~ for the Ca~V~1.4 ICDI was measured in [Fig. 2a](#F2){ref-type="fig"}, and the remaining *K*~d-FRET-peptide~ values are deduced in [Fig. 4b](#F4){ref-type="fig"}. The resulting linear plot ([Fig. 4c](#F4){ref-type="fig"}) argues that ICDI/IQ binding indeed underlies holochannel competition, and apoCaM/channel preassociation involves the IQ with *K*~d-channel~ \~10 nM ([Fig. 3e](#F3){ref-type="fig"}, [Supplemental 4.1](#SD2){ref-type="supplementary-material"}).

Transforming the reciprocal plots ([Fig. 4a](#F4){ref-type="fig"}) into normal format raises diverse biological implications ([Fig. 4d](#F4){ref-type="fig"}). The dogma has been that Ca^2+^ channels exhibit an ultra-strong apoCaM affinity^[@R8]^, ensuring maximal CDI over the green biological range^[@R23]^, as confirmed for channels lacking ICDI ([Fig. 4d](#F4){ref-type="fig"}, gray curve). Earlier reports that ICDI simply 'switches off' CDI^[@R11],[@R12]^ further promoted this perceived dissociation of CDI and apoCaM fluctuations. By contrast, we show here that the ICDI retunes *CDI*--\[apoCaM\] relations, so that natural variations of apoCaM modulate CDI and overall Ca^2+^ entry ([Fig. 4d](#F4){ref-type="fig"}). Such interconnection opens new vistas, given the widespread impact and distribution of Ca~V~1.3 and Ca~V~1.4 channels^[@R13]-[@R15]^, and the regulation of CaM^[@R23]^. For example, coexpressing neuromodulin (a bio-molecule that impacts synaptic growth/remodeling/plasticity and buffers apoCaM^[@R24]^) with the long variant of human Ca~V~1.3 channels indeed lowers apoCaM sufficiently to eliminate CDI and promote Ca^2+^ entry ([Fig. 4e](#F4){ref-type="fig"}, [Supplemental 4.3](#SD2){ref-type="supplementary-material"}). This outcome may bear on schizophrenia, where hippocampal neuromodulin is decreased^[@R25]^. Moreover, neurodegenerative diseases are potentially affiliated with Ca^2+^ dysregulation and thereby altered apoCaM^[@R26]^. In Parkinson's, excess alpha-synuclein is pathogenic^[@R27]^; these molecules bind apoCaM^[@R28]^; and elevated substantia-nigral Ca~V~1.3 activity predisposes for disease^[@R29]^. In Alzheimer's, CaM is depleted^[@R26]^. More broadly, certain heart failure models feature elevated CaM^[@R30]^. In all, exploring the (patho) physiological sequelae of Ca^2+^ channel connectivity with CaM now beckons at the frontier.

Methods {#S6}
=======

Molecular biology {#S7}
-----------------

Engineering of the rat Ca~V~1.3 long variant (α~1D~, AF370009.1) were made as follows. For [Fig. 1](#F1){ref-type="fig"}, a unique XbaI site was introduced by PCR following the IQ domain. The DCT of human α~1F~ (NP005174) was amplified and cloned non-directionally via the unique XbaI site, yielding the sequence in [Supplemental 1.1](#SD2){ref-type="supplementary-material"}. For [Fig. S3.4](#SD2){ref-type="supplementary-material"}, a like process was repeated, except appropriate sections of the DCT of rat Ca~V~1.3 long variant (α~1D~, AF370009.1) were first PCR amplified with flanking SpeI and XbaI sites (compatible ends), and cloned into the aforementioned unique XbaI site, leaving a unique XbaI site after the inserted section of the rat DCT. Appropriate segments of the ICDI segment of the human Ca~V~1.3 long variant (α~1D~, NM000718) were then PCR amplified with flanking SpeI and XbaI sites, and cloned into the unique XbaI site, leaving a unique XbaI site after the inserted ICDI segment. For the V41A insertion ([Fig. S3.4d](#SD2){ref-type="supplementary-material"}), the human ICDI was point mutated via QuikChange^®^ Mutagenesis (Strategene) prior to PCR amplification and insertion into the channel construct. For the A41V insertion ([Fig. S3.4e](#SD2){ref-type="supplementary-material"}), the rat ICDI was similar point mutated before cloning into the unique XbaI site of the aforementioned engineered rat Ca~V~1.3 long variant. For FRET 2-hybrid constructs, fluorophore-tagged CaM constructs were made as described^[@R6]^. Other FRET constructs made by replacing CaM with appropriate PCR amplified segments, via unique NotI and XbaI sites flanking CaM^[@R6]^. Details of CaM sponges in [Supplemental 3.1](#SD2){ref-type="supplementary-material"}. All segments subject to PCR or QuikChange^®^ were verified in their entirety by sequencing.

Transfection of HEK293 cells {#S8}
----------------------------

For electrophysiology experiments, HEK293 cells were cultured in 10 cm plates, and channels were transiently transfected by a calcium phosphate protocol^[@R6],[@R8]^. We applied 8 μg of cDNA encoding the desired channel α~1~ subunit, along with 8 μg of rat brain β~2a~ (M80545) and 8 μg of rat brain α~2~δ (NM012919.2) subunits. β~2a~ minimized voltage inactivation, enhancing resolution of CDI. Additional cDNA was added as required in co-transfections. All of the above cDNA constructs were driven by a cytomegalovirus promoter. To enhance expression, cDNA for simian virus 40 T antigen (1-2 μg) was co-transfected. For fluorescence resonance energy transfer (FRET) 2-hybrid experiments, transfections and experiments were performed as described^[@R6]^. Electrophysiology and FRET were done at room temperature 1--2 d after transfection.

Whole-cell recording {#S9}
--------------------

Whole-cell recordings were obtained at room temperature using an Axopatch 200A amplifier (Axon Instruments). Electrodes were pulled with borosilicate glass capillaries (World Precision Instruments, MTW 150-F4), resulting in 1--3 MΩ resistances, before series resistance compensation of 80%. The internal solutions contained, (in mM): CsMeSO~3~, 135; CsCl~2~, 5; MgCl~2~, 1; MgATP, 4; HEPES (pH 7.3), 5; and EGTA, 5; at 290 mOsm adjusted with glucose. The bath solution contained (in mM): TEA-MeSO~3~, 140; HEPES, 10, pH 7.3; CaCl~2~ or BaCl~2~, 10; 300 mOsm, adjusted with glucose. These are as reported^[@R8]^. To augment currents for the full-length Ca~V~1.4 experiments in [Fig. 2e](#F2){ref-type="fig"}, we used 40 mM CaCl~2~ or BaCl~2~ in the bath solution, while adjusting TEA-MeSO~3~ downwards to preserve osmolarity. As well, 5 μM Bay K 8644 was present in the bath throughout to further enhance currents.

FRET optical imaging {#S10}
--------------------

FRET 2-hybrid experiments were carried out in HEK293 cells and analyzed as described^[@R6]^. During imaging, the bath solution was either a Tyrode's buffer containing 2 mM Ca^2+^, or the standard electrophysiological recording bath solution described above. Concentration-dependent spurious FRET was subtracted from the raw data prior to binding-curve analysis^[@R17]^. For simultaneous BSCaM~IQ~ imaging and patch-clamp recording, three-cube FRET measurements were obtained prior to whole-cell break in, and did not change appreciably thereafter. For ICDI binding curves in [Figs. 2a](#F2){ref-type="fig"} and [4b](#F4){ref-type="fig"}, unlabelled IQ domain of neuromodulin (sequence in [Supplemental 3.1](#SD2){ref-type="supplementary-material"}) was coexpressed to reduce interference from endogenous CaM.

Supplementary Material {#S11}
======================

We thank Michael Tadross, Ivy Dick, and members of the Ca^2+^ signals lab for valuable comments; Michael Tadross for custom and elegant data-acquisition software; D.J. Black and Anthony Persechini for BSCaM~IQ~ and neuromodulin cDNA; J. McRory and Terry Snutch for human α~1F~ cDNA; J. Streissnig for the human α~1D~ cDNA; and Vincent Wu for earlier foundational experiments. Supported by grants from the NIMH (to D.T.Y.), NHLBI (D.T.Y.), and NIDCD (D.T.Y. and Paul Fuchs).

**Author contributions**

X.L. devised and refined experimental design; carried out all phases of the experiments; and performed extensive data analysis. P.S.Y. consulted on initial molecular biology approaches; constructed certain channels with ICDI point mutations; and contributed importantly to Ca~V~1.4 expression strategies and electrophysiological characterization. W.Y. conducted FRET experiments; undertook molecular biology; and extensively managed technical aspects of the project. D.T.Y. conceived, refined, and oversaw the experiments; performed FRET experiments; analyzed data; and wrote the manuscript. All authors commented on and edited the manuscript.

![Distal carboxy tail of Ca~V~1.4 weakens Ca^2+^ regulation of channels\
**a**, Core Ca~V~1.3 channel contains all known structural elements required for CDI (left schematic of main subunit α~1DΔ~, containing NSCaTE^[@R17]^, EF^[@R18]^, and IQ^[@R6]^) and thereby exhibits robust CDI (right two sub-panels). Average *f*~50~ CDI metric at bottom (mean ± sem), with number of cells in parentheses. Throughout, current bars pertain to Ca^2+^ currents, Ba^2+^ currents scaled for kinetic comparison, and tail currents clipped to frame. **b**, Adding DCT of α~1F~ (main pore-forming Ca~V~1.4 subunit) to core Ca~V~1.3 channel weakens CDI. A, B, and ICDI segments of DCT defined in [Supplemental 1.1](#SD2){ref-type="supplementary-material"}. Dashed curve reproduces baseline from **a**.](nihms165356f1){#F1}

![Provisional evidence for competition\
**a**, FRET, CFP-tagged ICDI of α~1F~ versus YFP-tagged PreIQ~3~-IQ-A from [Fig. 1b](#F1){ref-type="fig"} ([Supplemental 2.1](#SD2){ref-type="supplementary-material"}). *FR* ∝ FRET efficiency times fraction of YFP-tagged molecules bound^[@R6]^. *D*~free~, relative concentration of unbound CFP-tagged molecules; green bar \~500 nM^[@R6]^. **b**, FRET, apoCaM versus PreIQ~3~-IQ-A in **a**. **c**, ICDI (without fluorophore) attenuates binding in **b**. Gray reference curve from **b**. **d**, Left, CDI is rescued upon overexpressing CaM with chimera in [Fig. 1b](#F1){ref-type="fig"}. Right, CaM sponge (Ca~V~1.2 YFP--PreIQ~3~-IQ^[@R6]^) eliminates CDI. **e**, Overexpressing CaM with full-length Ca~V~1.4. *f*~300~, 300-ms version of *f*~50~.](nihms165356f2){#F2}

![Live-cell holochannel biochemistry proves competition\
**a**, BSCaM~IQ~ schematic. **b**, BSCaM~IQ~ expressed alone (black curve and data), and coexpressed with CaM or CaM sponges (neuromodulin IQ (filled green, [Supplemental 3.1](#SD2){ref-type="supplementary-material"}) or Ca~V~1.2 PreIQ~3~-IQ^[@R6]^ (open green)). *S*~CFP~, isolated CFP fluorescence^[@R6]^. **c**, Approach to obtain CDI and FRET readouts of apoCaM (*FR*) in single cells. **d**, *CDI--S*~b~ analysis for α~1DΔ\[rat\]~--(ABI)~F~, respectively, for -10 mV steps. Right, family of gray *CDI--S*~b~ curves illustrate potential profiles for competitive inhibition, according to [Eq. 1](#FD1){ref-type="disp-formula"}. Superimposed red data and fit conform to competitive profile. Left, corresponding exemplar traces, labelled i-iii. **e-g**, *CDI--S*~b~ analysis for α~1DΔ\[rat\]~, α~1D--long\[hum\]~, and α~1D--long\[rat\]~. Format as in **d**.](nihms165356f3){#F3}

![Molecular interactions and biology of competitive inhibitory tuning\
**a**, Reciprocal-plot representation of [Fig. 3 (d-g)](#F3){ref-type="fig"} relations. **b**, FRET assays characterizing presumed peptide interactions underlying holochannel competition (as in **a**). **c**, Linear relation between holochannel and peptide competition parameters. **d**, Linear format of quantitative tuning relations. Green biological range, 99% boundaries^[@R23]^. **e**, Consequences of connectivity in long variant of human Ca~V~1.3. Natural variability of native CaM buffers (neuromodulin) affects CDI and Ca^2+^ entry for long variant of human Ca~V~1.3. Left, CaM coexpression; middle, endogenous CaM; right, neuromodulin coexpression.](nihms165356f4){#F4}
